Literature DB >> 23008318

Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up.

Hege S Haugnes1, George J Bosl, Hink Boer, Jourik A Gietema, Marianne Brydøy, Jan Oldenburg, Alv A Dahl, Roy M Bremnes, Sophie D Fosså.   

Abstract

Germ cell testicular cancer (TC) represents a malignancy with high cure rates. Since the introduction of cisplatin-based chemotherapy in the late 1970s, the 5-year survival rate has increased considerably, and it is currently above 95%. Because TC is usually diagnosed before the age of 40 years, these men can expect to live for another 40 to 50 years after being successfully treated. This success, however, is hampered by an increased risk of long-term and late effects of treatment. Secondary malignant neoplasms and cardiovascular disease represent the most common potentially life-threatening late effects, typically occurring more than 10 years after treatment. Other long-term effects include pulmonary toxicity, nephrotoxicity, neurotoxicity, decreased fertility, hypogonadism, and psychosocial problems. The incidence and time to onset of these various adverse effects vary according to treatment type and intensity. There is still little knowledge about underlying mechanisms and genetic susceptibility of the various adverse effects. Apart from treatment burden, it is not yet possible to identify patients who are at high risk for certain late effects after TC treatment. In this clinical review, we present the current status regarding different somatic and psychosocial long-term late effects after treatment for TC, based on Medline searches and our own research. Moreover, we postulate recommendations for general medical evaluations that should begin after treatment is completed and continue during follow-up.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23008318     DOI: 10.1200/JCO.2012.43.4431

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  68 in total

1.  Is orchiectomy always necessary in retroperitoneal extragonadal germ cell tumours?

Authors:  Robert J Hamilton
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

2.  Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors.

Authors:  Samuel A Funt; Sujata Patil; Darren R Feldman; Robert J Motzer; Dean F Bajorin; Joel Sheinfeld; Satish K Tickoo; Victor E Reuter; George J Bosl
Journal:  J Clin Oncol       Date:  2019-06-24       Impact factor: 44.544

Review 3.  Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators.

Authors:  Joana Caiado; Matthieu Picard
Journal:  Curr Allergy Asthma Rep       Date:  2014-08       Impact factor: 4.806

4.  Long-term health effects among testicular cancer survivors.

Authors:  Mia Hashibe; Sarah Abdelaziz; Mohammed Al-Temimi; Alison Fraser; Kenneth M Boucher; Ken Smith; Yuan-Chin Amy Lee; Kerry Rowe; Braden Rowley; Micky Daurelle; Avery E Holton; James VanDerslice; Lorenzo Richiardi; Jay Bishoff; Will Lowrance; Antoinette Stroup
Journal:  J Cancer Surviv       Date:  2016-05-11       Impact factor: 4.442

5.  The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study.

Authors:  Allan Ben Smith; Phyllis Butow; Ian Olver; Tim Luckett; Peter Grimison; Guy C Toner; Martin R Stockler; Elizabeth Hovey; John Stubbs; Sandra Turner; George Hruby; Howard Gurney; Mahmood Alam; Keith Cox; Madeleine T King
Journal:  J Cancer Surviv       Date:  2015-07-16       Impact factor: 4.442

6.  "Off-Label" Usage of Testicular Self-Examination (TSE): Benefits Beyond Cancer Detection.

Authors:  Michael J Rovito; James E Leone; Chase T Cavayero
Journal:  Am J Mens Health       Date:  2015-05-19

7.  The Sound of Silence: A Proxy for Platinum Toxicity.

Authors:  Jan Oldenburg; Jourik A Gietema
Journal:  J Clin Oncol       Date:  2016-07-05       Impact factor: 44.544

8.  Management of testicular cancer: NYU case of the month, March 2017.

Authors:  James S Wysock
Journal:  Rev Urol       Date:  2017

Review 9.  Cardiovascular prevention in the cancer survivor.

Authors:  Carol L Chen
Journal:  Curr Atheroscler Rep       Date:  2015-03       Impact factor: 5.113

10.  Second malignancies in long-term testicular cancer survivors.

Authors:  D Ondrus; M Ondrusova; L Friedova
Journal:  Int Urol Nephrol       Date:  2013-10-06       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.